DCGI previously authorized Cipla and Hetero to manufacture and market remdesivir
New Delhi:
The Drug Controller General of India (DCGI) has authorized Mylan laboratories to manufacture and market remdesivir, an antiviral drug intended for “ restricted emergency use ” on COVID-19 hospital patients, a senior official said Thursday. government official.
DCGI previously authorized Cipla and Hetero to manufacture and market remdesivir. ANI reported last month that the DCGI office of the Central Drug Control Standard Organization (CDCSO) had granted Gilead Sciences, based in the United States, the authorization to market its antiviral drug remdesivir in India for “ use of ‘restricted emergency’ on hospitalized COVIDs -19 patients.
Gilead had signed non-exclusive voluntary license agreements with five generic pharmaceutical companies – Cipla, Jubilant Life Sciences, Hetero, BRD and Mylan to manufacture and distribute remdesivir, a potential antiviral treatment for COVID-19.
(With the exception of the title, this story was not edited by GalacticGaming staff and is published from a syndicated feed.)
